Joaquin Duato, CEO of J&J, stated: “Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add US-based jobs but manufacture cutting-edge medicines to treat patients in America and around the world.”

The announced additional investments kicked off with the groundbreaking of a new biologics manufacturing facility in Wilson, North Carolina. This facility will expand J&J's capacity to manufacture next-generation medicines for people living with cancer, immune-mediated, and neurological diseases and is expected to create over 500 new positions at the site.

In addition to the new site in Wilson, the J&J’s plans include three new manufacturing facilities and the expansion of several existing sites across the company’s Innovative Medicine and MedTech businesses, as well as “significant” investments in R&D infrastructure and technology